SNDX Q3 2022 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$35M

Net Income

-$35M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$360M

Total Liabilities

$22M

Stockholders' Equity

$338M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$12M	-100.0%
Gross Profit	$0	$12M	-100.0%
Operating Income	-$35M	-$20M	-75.4%
Net Income	-$35M	-$21M	-71.5%